JB Capital LLC Buys 1,150 Shares of Incyte Co. (NASDAQ:INCY)

JB Capital LLC raised its position in Incyte Co. (NASDAQ:INCY) by 2.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,628 shares of the biopharmaceutical company’s stock after buying an additional 1,150 shares during the quarter. JB Capital LLC’s holdings in Incyte were worth $3,082,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INCY. MFA Wealth Advisors LLC acquired a new stake in shares of Incyte during the 2nd quarter valued at $26,000. Innealta Capital LLC bought a new position in Incyte during the 2nd quarter worth approximately $32,000. Cromwell Holdings LLC lifted its holdings in Incyte by 101.1% in the third quarter. Cromwell Holdings LLC now owns 563 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 283 shares during the period. Fidelis Capital Partners LLC bought a new stake in shares of Incyte during the 1st quarter valued at about $32,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Incyte during the 2nd quarter worth approximately $36,000. 96.97% of the stock is currently owned by institutional investors.

Incyte Stock Down 0.2 %

Shares of INCY stock traded down $0.13 during trading hours on Thursday, reaching $80.82. 291,711 shares of the company’s stock were exchanged, compared to its average volume of 2,329,971. Incyte Co. has a 1 year low of $50.35 and a 1 year high of $82.19. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01. The stock has a market cap of $15.57 billion, a PE ratio of 578.26, a PEG ratio of 8.73 and a beta of 0.71. The stock’s fifty day moving average price is $66.79 and its two-hundred day moving average price is $62.43.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.12). The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.08 billion. Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The company’s quarterly revenue was up 23.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.91 earnings per share. Research analysts predict that Incyte Co. will post 0.4 EPS for the current year.

Insiders Place Their Bets

In other Incyte news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.36, for a total transaction of $526,942.00. Following the sale, the executive vice president now directly owns 36,390 shares of the company’s stock, valued at approximately $2,269,280.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total transaction of $526,942.00. Following the sale, the executive vice president now owns 36,390 shares of the company’s stock, valued at $2,269,280.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas Tray sold 572 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the sale, the insider now owns 24,825 shares in the company, valued at approximately $1,562,485.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on INCY. Royal Bank of Canada upped their price target on Incyte from $67.00 to $72.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 30th. Citigroup lifted their target price on shares of Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Morgan Stanley raised their price objective on shares of Incyte from $64.00 to $69.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Wells Fargo & Company upped their price objective on shares of Incyte from $62.00 to $68.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Finally, William Blair reiterated an “outperform” rating on shares of Incyte in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Incyte presently has an average rating of “Hold” and a consensus target price of $76.74.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.